XJPX
4028
Market cap672mUSD
Oct 09, Last price
2,814.00JPY
1D
1.33%
1Q
1.70%
Jan 2017
206.54%
Name
Ishihara Sangyo Kaisha Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ishihara Sangyo Kaisha, Ltd. is a global producer and distributor of both organic and inorganic chemicals, with its operations spanning Japan, Asia, the United States, Europe, and other international markets. A key segment of its product line consists of TIPAQUE brand titanium dioxide (TiO2) offerings. These encompass white pigments, widely utilized in the production of items such as paints, inks, plastics, and paper, alongside yellow pigments. Additionally, the company provides an array of functional materials, including ultrafine TiO2, ultrafine ZnO, electro-conductive substances, photocatalytic TiO2, high-purity TiO2, titanium tetrachloride, TiO2 for catalytic applications, acicular TiO2, glass coatings, and battery components. Its broader chemical portfolio also features matting agents, heat-shielding substances, and various agrochemicals like herbicides, fungicides, insecticides, and nematicides. Furthermore, Ishihara Sangyo supplies animal healthcare products, pharmaceutical reagents, and CF3-Pyridine organic intermediates specifically for pharmaceutical research. The company, which maintains its corporate headquarters in Osaka, Japan, was established in 1920.
Key people
Hiroshi Okubo
President, Executive President, Chief Compliance Officer, Representative Director · since 2024
Mikiya Horie
Senior Managing Executive Officer, Chief Director of Bioscience Business, Representative Director · since 2024
Yasunobu Kawazoe
Senior Managing Executive Officer, Chief Director of Finance, Director · since 2024
Shigeru Mitani
Managing Executive Officer, Senior Manager of Environment, Safety and Quality · since 2024
Yoshiyuki Shimmyo
Managing Executive Officer, Chief Director of Inorganic Chemicals, Director · since 2024
Toichiro Shiomi
Managing Executive Officer, Chief Director of Finance · since 2025
Kenji Tanaka
Managing Executive Officer, Chief Director of Corporate Administration & Planning · since 2024
Hiroyuki Watanabe
Managing Executive Officer, Chief Director of Healthcare Business · since 2024
Ikuo Yamashita
Managing Executive Officer, Yokkaichi Plant Manager, Director · since 2025
Hiroshi Shikama
Executive Officer, Deputy Chief Director of Healthcare Business, Director of Animal Health Sales in Main Healthcare Business Unit · since 2024
Tetsuya Ikeda
Executive Officer, Director of Human Resources in General Affairs and Human Resource Unit · since 2025
Yoshio Nishiyama
Managing Executive Officer, Chief Director of Human Resources and General Affairs, Director · since 2024
Satoshi Araki
Executive Officer, Director of Central Research Institute · since 2024
Shunsuke Asano
Executive Officer, Deputy Chief Director of Inorganic Chemicals Business, Manager of Yokkaichi Plant · since 2024
Akihiko Kikuchi
Executive Officer, Chief Director of Legal · since 2024
Yasushi Nakao
Executive Officer, Deputy Chief Director of Inorganic Chemicals Business · since 2024
Masateru Oguri
Executive Officer, Deputy Chief Director of Biosciences Business · since 2024
Tooru Sakamoto
Executive Officer, Deputy Chief Director of Inorganic Chemicals Business · since 2024
Makiko Sano
Executive Officer, Manager of Sustainability Promotion · since 2024
Kenichiro Tsunoda
Executive Officer, Deputy Chief Director of Business Planning Administration, Director of Administration in Business Planning Administration Unit · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||